Allos third quarter net loss decreases to $11.

Allos third quarter net loss decreases to $11 journal .2 million Allos Therapeutics, Inc. today reported economic results for the three months ended September 30, 2011.2 million in the third quarter of 2011, in comparison to $8.2 million for the same period this year 2010. As of 30 September, 2011, the Company had no debt and $100.4 million altogether cash, cash equivalents and investments. ‘We believe our achievement of significant year-over-year revenue growth reflects increased disease-state awareness and brand awareness of FOLOTYN for patients with relapsed or refractory peripheral T-cell lymphoma, for whom there remains an unmet need,’ commented Paul L.

Allopurinol has been shown to decrease levels of C-reactive protein previously, slow down progression of renal disease, and decrease hospitalization and CV risk in CKD sufferers, write the researchers. ‘If such beneficial effects are also evident in hypertensive topics with lower GFR, then your CV risk of these subjects could be suppressed with allopurinol.’ Licensed from medwireNews with authorization from Springer Healthcare Ltd. All rights reserved. Neither of the ongoing celebrations endorse or recommend any commercial products, services, or equipment.. Allopurinol might improve CV outcomes in kidney disease By Sally Robertson, medwireNews Reporter The xanthine oxidase inhibitor allopurinol appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality in sufferers with hypertensive nephropathy, show findings from a Japanese study.